Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q969M3
UPID:
YIPF5_HUMAN
Alternative names:
Five-pass transmembrane protein localizing in the Golgi apparatus and the endoplasmic reticulum 5; Smooth muscle cell-associated protein 5; YIP1 family member 5; YPT-interacting protein 1 A
Alternative UPACC:
Q969M3; D3DQF5; Q4VSN6; Q53EX4; Q8NHE5; Q9H338; Q9H3U4
Background:
Protein YIPF5, known for its pivotal role in transport between the endoplasmic reticulum and Golgi, is essential in pancreatic beta cells for proinsulin transport. It is recognized by alternative names such as Five-pass transmembrane protein localizing in the Golgi apparatus and the endoplasmic reticulum 5, Smooth muscle cell-associated protein 5, YIP1 family member 5, and YPT-interacting protein 1 A.
Therapeutic significance:
Linked to Microcephaly, epilepsy, and diabetes syndrome 2, Protein YIPF5's understanding could pave the way for innovative therapeutic strategies targeting this autosomal recessive disorder.